PLoS ONE (Jan 2023)

Multimorbidity patterns in COVID-19 patients and their relationship with infection severity: MRisk-COVID study

  • Marina Lleal,
  • Celia Corral-Vazquez,
  • Montserrat Baré,
  • Ricard Comet,
  • Susana Herranz,
  • Francisco Baigorri,
  • Antonio Gimeno-Miguel,
  • Maria Raurich,
  • Cristina Fortià,
  • Marta Navarro,
  • Beatriz Poblador-Plou,
  • Marisa Baré

Journal volume & issue
Vol. 18, no. 8

Abstract

Read online

Background Several chronic conditions have been identified as risk factors for severe COVID-19 infection, yet the implications of multimorbidity need to be explored. The objective of this study was to establish multimorbidity clusters from a cohort of COVID-19 patients and assess their relationship with infection severity/mortality. Methods The MRisk-COVID Big Data study included 14 286 COVID-19 patients of the first wave in a Spanish region. The cohort was stratified by age and sex. Multimorbid individuals were subjected to a fuzzy c-means cluster analysis in order to identify multimorbidity clusters within each stratum. Bivariate analyses were performed to assess the relationship between severity/mortality and age, sex, and multimorbidity clusters. Results Severe infection was reported in 9.5% (95% CI: 9.0–9.9) of the patients, and death occurred in 3.9% (95% CI: 3.6–4.2). We identified multimorbidity clusters related to severity/mortality in most age groups from 21 to 65 years. In males, the cluster with highest percentage of severity/mortality was Heart-liver-gastrointestinal (81–90 years, 34.1% severity, 29.5% mortality). In females, the clusters with the highest percentage of severity/mortality were Diabetes-cardiovascular (81–95 years, 22.5% severity) and Psychogeriatric (81–95 years, 16.0% mortality). Conclusion This study characterized several multimorbidity clusters in COVID-19 patients based on sex and age, some of which were found to be associated with higher rates of infection severity/mortality, particularly in younger individuals. Further research is encouraged to ascertain the role of specific multimorbidity patterns on infection prognosis and identify the most vulnerable morbidity profiles in the community. Trial registration NCT04981249. Registered 4 August 2021 (retrospectively registered).